HealthDay News — Preexisting statin treatment is associated with slightly lower COVID-19 mortality, according to a study published online Oct. 14 in PLOS Medicine.

Rita Bergqvist, from the Karolinska Institutet in Stockholm, and colleagues assessed the relationship between statin treatment initiated before the pandemic and COVID-19 mortality among 963,876 Stockholm residents (ages 45 years or older).

The researchers reported that 17.6 percent of the patients in the cohort were statin users. COVID-19-related deaths occurred in 0.5 percent of the statin users and 0.2 percent of nonusers. In an adjusted analysis, statin treatment was associated with lowered COVID-19 mortality (adjusted hazard ratio, 0.88). This association remained consistent across age groups, sexes, and COVID-19 risk groups.

Continue Reading

“Our findings support the continued use of statins for conditions such as cardiovascular disease and high levels of blood lipids in line with current recommendations during the COVID-19 pandemic,” a coauthor said in a statement.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text